Is Galmed Pharmaceuticals Stock a Good Investment?
Galmed Pharmaceuticals Investment Advice | GLMD |
- Examine Galmed Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Galmed Pharmaceuticals' leadership team and their track record. Good management can help Galmed Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Galmed Pharmaceuticals' business and its evolving consumer preferences.
- Compare Galmed Pharmaceuticals' performance and market position to its competitors. Analyze how Galmed Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Galmed Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Galmed Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Galmed Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Galmed Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Galmed Pharmaceuticals Stock
Researching Galmed Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 0.26. Some equities with similar Price to Book (P/B) outperform the market in the long run. Galmed Pharmaceuticals recorded earning per share (EPS) of 69.72. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 30th of August 2024.
To determine if Galmed Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Galmed Pharmaceuticals' research are outlined below:
| Galmed Pharmaceuticals is way too risky over 90 days horizon | |
| Galmed Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (6.91 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galmed Pharmaceuticals currently holds about 22.4 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Galmed Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Galmed Pharmaceuticals Stock Crosses Below 200 Day Moving Average Time to Sell |
Galmed Pharmaceuticals Quarterly Accounts Payable |
|
Galmed Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Galmed Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Galmed Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Galmed Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Galmed Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-22 | 2023-09-30 | -0.27 | -0.24 | 0.03 | 11 | ||
2019-05-07 | 2019-03-31 | -0.2 | -0.17 | 0.03 | 15 | ||
2023-03-29 | 2022-12-31 | -0.14 | -0.1 | 0.04 | 28 | ||
2016-08-03 | 2016-06-30 | -0.35 | -0.39 | -0.04 | 11 | ||
2015-08-13 | 2015-06-30 | -0.25 | -0.21 | 0.04 | 16 | ||
2022-11-16 | 2022-09-30 | -0.16 | -0.21 | -0.05 | 31 | ||
2021-11-08 | 2021-09-30 | -0.36 | -0.31 | 0.05 | 13 | ||
2021-08-05 | 2021-06-30 | -0.38 | -0.33 | 0.05 | 13 |
Know Galmed Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Galmed Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Galmed Pharmaceuticals backward and forwards among themselves. Galmed Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Galmed Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Zrc Wealth Management, Llc | 2024-09-30 | 1.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 | Two Sigma Advisers, Llc | 2024-06-30 | 0.0 | Walleye Trading Advisors, Llc | 2024-06-30 | 290.6 K | Cvi Holdings Llc | 2024-06-30 | 47.2 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 36.2 K | Susquehanna International Group, Llp | 2024-06-30 | 11.6 K | Two Sigma Securities, Llc | 2024-06-30 | 10.3 K | Ubs Group Ag | 2024-06-30 | 280 | Wells Fargo & Co | 2024-06-30 | 204 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 167 |
Galmed Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.76 M.Market Cap |
|
Galmed Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | 0.54 | 0.57 | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.50) | (0.47) |
Determining Galmed Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Galmed Pharmaceuticals is a good buy. For example, gross profit margin measures Galmed Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Galmed Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Galmed Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Galmed Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Galmed Pharmaceuticals' management manipulating its earnings.
Evaluate Galmed Pharmaceuticals' management efficiency
Galmed Pharmaceuticals has return on total asset (ROA) of (0.2931) % which means that it has lost $0.2931 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5267) %, meaning that it created substantial loss on money invested by shareholders. Galmed Pharmaceuticals' management efficiency ratios could be used to measure how well Galmed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.57, whereas Return On Tangible Assets are forecasted to decline to (0.44). At present, Galmed Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 9.93, whereas Other Current Assets are forecasted to decline to about 410.4 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 60.34 | 63.36 | |
| Tangible Book Value Per Share | 60.34 | 63.36 | |
| Enterprise Value Over EBITDA | 0.23 | 0.25 | |
| Price Book Value Ratio | 0.09 | 0.09 | |
| Enterprise Value Multiple | 0.23 | 0.25 | |
| Price Fair Value | 0.09 | 0.09 | |
| Enterprise Value | 171.1 M | 162.6 M |
Galmed Pharmaceuticals has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 0.798 |
Basic technical analysis of Galmed Stock
As of the 28th of November, Galmed Pharmaceuticals retains the Market Risk Adjusted Performance of (0.56), risk adjusted performance of 0.0642, and Downside Deviation of 11.12. Galmed Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Galmed Pharmaceuticals treynor ratio, and the relationship between the variance and potential upside to decide if Galmed Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 2.86 per share. Please also validate Galmed Pharmaceuticals total risk alpha, which is currently at (3.24) to confirm the company can sustain itself at a future point.Galmed Pharmaceuticals' Outstanding Corporate Bonds
Galmed Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Galmed Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Galmed bonds can be classified according to their maturity, which is the date when Galmed Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Galmed Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Galmed Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0642 | |||
| Market Risk Adjusted Performance | (0.56) | |||
| Mean Deviation | 12.1 | |||
| Semi Deviation | 10.0 | |||
| Downside Deviation | 11.12 | |||
| Coefficient Of Variation | 1406.24 | |||
| Standard Deviation | 37.37 | |||
| Variance | 1396.55 | |||
| Information Ratio | 0.0676 | |||
| Jensen Alpha | 3.21 | |||
| Total Risk Alpha | (3.24) | |||
| Sortino Ratio | 0.2272 | |||
| Treynor Ratio | (0.57) | |||
| Maximum Drawdown | 344.49 | |||
| Value At Risk | (13.40) | |||
| Potential Upside | 21.71 | |||
| Downside Variance | 123.71 | |||
| Semi Variance | 100.05 | |||
| Expected Short fall | (20.48) | |||
| Skewness | 7.17 | |||
| Kurtosis | 56.08 |
| Risk Adjusted Performance | 0.0642 | |||
| Market Risk Adjusted Performance | (0.56) | |||
| Mean Deviation | 12.1 | |||
| Semi Deviation | 10.0 | |||
| Downside Deviation | 11.12 | |||
| Coefficient Of Variation | 1406.24 | |||
| Standard Deviation | 37.37 | |||
| Variance | 1396.55 | |||
| Information Ratio | 0.0676 | |||
| Jensen Alpha | 3.21 | |||
| Total Risk Alpha | (3.24) | |||
| Sortino Ratio | 0.2272 | |||
| Treynor Ratio | (0.57) | |||
| Maximum Drawdown | 344.49 | |||
| Value At Risk | (13.40) | |||
| Potential Upside | 21.71 | |||
| Downside Variance | 123.71 | |||
| Semi Variance | 100.05 | |||
| Expected Short fall | (20.48) | |||
| Skewness | 7.17 | |||
| Kurtosis | 56.08 |
Consider Galmed Pharmaceuticals' intraday indicators
Galmed Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Galmed Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Galmed Pharmaceuticals Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 28th of October 2024 Other Reports | ViewVerify | |
6K | 21st of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 20th of September 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Galmed Stock media impact
Far too much social signal, news, headlines, and media speculation about Galmed Pharmaceuticals that are available to investors today. That information is available publicly through Galmed media outlets and privately through word of mouth or via Galmed internal channels. However, regardless of the origin, that massive amount of Galmed data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Galmed Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Galmed Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Galmed Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Galmed Pharmaceuticals alpha.
Galmed Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Galmed Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Galmed Pharmaceuticals Corporate Management
| Shani Ganon | Human Manager | Profile | |
| Tali Gorfine | Medical Consultant | Profile | |
| Yael Hollander | Vice Strategy | Profile | |
| Guy Nehemya | COO Officer | Profile | |
| Niv Alon | Head PMO | Profile | |
| Doron Cohen | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 69.72 | Return On Assets (0.29) | Return On Equity (0.53) |
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Galmed Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.